Physician profile
Roger Mayorga
NPI 1053491878
$9,746.72
in general payments reported to CMS, 2019-2025
27 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $2,100 · 2023: $2,342 · 2024: $2,367 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,942 · Education: $13.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,942.16 |
| Education | $13.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,980.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,216.06 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $952.19 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $697.82 | 2023-2025 | Auvelity |
| Corium, LLC | $653.95 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $540.47 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $520.01 | 2021-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $470.32 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $362.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $338.08 | 2021-2025 | Trintellix |
| Lundbeck LLC | $319.92 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $269.12 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $204.86 | 2021-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $184.12 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $160.71 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $126.28 | 2024-2025 | Zurzuvae |
| Neurocrine Biosciences, INC. | $121.91 | 2023-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $102.90 | 2022-2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $87.27 | 2024-2025 | Relexxii |
| Bausch Health US, LLC | $82.41 | 2022-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $78.16 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $74.43 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $69.06 | 2024-2025 | Xelstrym, Secuado |
| Harmony Biosciences LLC | $56.06 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $40.39 | 2022 | |
| Sage Therapeutics, LLC | $20.14 | 2022 | |
| Livanova USA, INC. | $16.21 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Mayorga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.